8-K: Evolus Q2 Revenue Up 4%; Resets 2025 Guidance Lower

Evolus, Inc. reported a 4% increase in Q2 2025 global net revenue to $69.4 million, driven by the successful Evolysse launch, but reset its full-year 2025 revenue guidance lower due to softened U.S. toxin demand.

Summary

• Global net revenue for Q2 2025 reached $69.4 million, a 4% increase compared to Q2 2024, primarily driven by the successful launch of Evolysse and strong international market performance.
• Evolysse, the company's injectable hyaluronic acid (HA) gel, generated $9.7 million in revenue for Q2 2025, marking the strongest filler launch quarter in over a decade.
• The company reset its full-year 2025 net revenue guidance to a range of $295 million to $305 million, representing 11% to 15% growth over 2024 results.
• Full-year 2025 non-GAAP operating expenses are now projected to be between $208 million and $213 million, reflecting strategic cost structure optimization expected to yield at least $25 million in savings.
• Evolus anticipates achieving meaningful profitability (positive non-GAAP operating income) in Q4 2025 and annual profitability starting in 2026.
• GAAP loss from operations for Q2 2025 was $10.2 million, compared to a loss of $7.7 million in Q2 2024.
• Non-GAAP loss from operations for Q2 2025 was $7.9 million, compared to non-GAAP income from operations of $1.1 million in Q2 2024.
• Cash and cash equivalents stood at $61.7 million as of June 30, 2025, down from $67.9 million on March 31, 2025, primarily due to increased inventory purchases ahead of potential tariffs.
• The company maintains its long-term goal of achieving $700 million in total net revenue and a 20% non-GAAP operating income margin by 2028.

Sentiment

Score: 4

Explanation: The sentiment is mixed to slightly negative. While there are clear positives like strong product launch performance and international growth, the lowered full-year revenue guidance, increased GAAP and non-GAAP operating losses, and a decrease in cash indicate near-term financial headwinds. The strategic cost optimization and maintained long-term targets provide some stability, but the immediate financial results and outlook are concerning.

Positives

• Global net revenue increased by 4% year-over-year to $69.4 million in Q2 2025.
• The launch of Evolysse generated $9.7 million in revenue for Q2 2025, marking the strongest filler launch quarter in over a decade.
• International business delivered exceptional growth, highlighting increasing global demand.
• Jeuveau continues to outperform the U.S. toxin market, maintaining a 14% market share through the first half of 2025.
• Total purchasing accounts increased by 565 in Q2, reaching over 16,500 customers and surpassing 55% account penetration in the U.S.
• The reorder rate among customers remains strong at approximately 70%.
• Evolus Rewards consumer loyalty program grew by over 83,000 members to over 1.2 million, a 36% increase compared to Q2 2024.
• Total Evolus Rewards redemptions hit an all-time high of over 224,000, with existing patients receiving repeat treatments at approximately 65%.
• Strategic cost structure optimization is expected to yield at least $25 million in non-GAAP operating expense savings for 2025.
• The company expects to achieve meaningful profitability in Q4 2025 and annual profitability beginning in 2026.
• Long-term goals of $700 million total net revenue and 20% non-GAAP operating income margin by 2028 are maintained.

Negatives

• U.S. toxin demand softened in Q2 2025 due to reduced patient demand and a sharp decrease in consumer sentiment.
• Gross profit margin decreased to 65.3% in Q2 2025 from 70.3% in Q2 2024, impacted by a higher mix of international sales and introductory pricing for Evolysse.
• GAAP loss from operations increased to $10.2 million in Q2 2025 from $7.7 million in Q2 2024.
• Non-GAAP loss from operations was $7.9 million in Q2 2025, a decline from non-GAAP income of $1.1 million in Q2 2024.
• Cash and cash equivalents decreased to $61.7 million on June 30, 2025, from $67.9 million on March 31, 2025.
• The company reset its full-year 2025 net revenue guidance, implying a downward revision from previous expectations.
• A 15% tariff on Evolysse will be applied starting August 7, 2025, due to a trade deal with the European Union.

Risks

• Uncertainties associated with the ability to comply with the terms and conditions in the Medytox Settlement Agreements.
• Ability to fund future operations or obtain financing to fund operations.
• Unfavorable global economic conditions, including trade disputes, tariffs, and the impact on consumer discretionary spending.
• Uncertainties related to customer and consumer adoption of Jeuveau and Evolysse.
• The efficiency and operability of the company's digital platform.
• Competition and market dynamics in the aesthetic injectable market.
• Ability to successfully launch and commercialize products in new markets, including Evolysse Hyaluronic Acid (HA) gels in the U.S. and Estyme HA gels in Europe.
• Ability to maintain regulatory approvals of Jeuveau and Evolysse or obtain regulatory approvals for new product candidates or indications.
• Reliance on Symatese to achieve and/or maintain regulatory approval for the Evolysse HA gel products in the U.S.

Future Outlook

Evolus projects full-year 2025 net revenues between $295 million and $305 million, with Evolysse injectable HA gels contributing 10% to 12% of total revenue. Non-GAAP operating expenses for 2025 are expected to be $208 million to $213 million due to strategic cost optimization. The company anticipates achieving meaningful profitability in Q4 2025 and annual profitability starting in 2026. Future product launches include Evolysse Sculpt in the U.S. in 2026 and Evolysse Lips in the U.S. in 2027. A broader European launch for Estyme is now planned for Q1 2026, following a limited experience program in H2 2025. Evolus maintains its long-term goal of $700 million in total net revenue and a 20% non-GAAP operating income margin by 2028.

Management Comments

• "U.S. toxin demand softened in the second quarter, driven by reduced patient demand due to a sharp decrease in consumer sentiment which resulted in accounts purchasing lower volumes acutely felt in the final two weeks of the quarter."
• "Despite these challenges, Jeuveau continues to outperform the market, maintaining our 14% market share through the first half of 2025 and reinforcing the strength of our brand and customer base."
• "At the same time, the launch of Evolysse surpassed all expectations and marked the strongest first quarter for any filler entrant in over a decade, providing a meaningful start to our evolution into a multi-product performance beauty company."
• "Our international business delivered exceptional growth, highlighting the increasing demand for our product outside the U.S. and the growing global relevance of our brand."
• "We took decisive action to offset the reduction in revenue and near-term outlook by optimizing our cost structure, thoughtfully reducing operating expenses, and to maintain our ability to achieve positive non-GAAP operating income in the fourth quarter."
• "The second quarter was not representative of our expectations for the back half of the year, which we project to deliver meaningful growth and keep us on track to achieve our $700 million revenue target by 2028."

Industry Context

The announcement reflects a broader trend of softened U.S. toxin demand in the aesthetic market, attributed to reduced patient demand and a sharp decrease in consumer sentiment. Despite these headwinds, Evolus's Jeuveau product is noted to be outperforming the market, maintaining its 14% market share. The successful launch of Evolysse, described as the strongest filler entrant in over a decade, indicates a strong performance in the hyaluronic acid filler segment, potentially capturing market share in a competitive landscape. The company's strategic cost optimization efforts are a direct response to the challenging market conditions.

Comparison to Industry Standards

• Evolysse's Q2 2025 revenue of $9.7 million marks the strongest first quarter for any filler entrant in over a decade, indicating a highly successful product launch relative to historical industry performance.
• Jeuveau maintained a 14% market share through the first half of 2025 and is noted to be outperforming the overall U.S. toxin market, suggesting stronger resilience compared to competitors in a period of softened demand.

Management Changes

Related Party Transactions

• Biographical information for David Moatazedi and information regarding certain related party transactions disclosable pursuant to Item 404(a) of Regulation S-K involving Mr. Moatazedi were reported in the company's Proxy Statement on Schedule 14A filed with the SEC on April 25, 2025.

Stakeholder Impact

• Shareholders: Impacted by revised lower revenue guidance, increased operating losses, and a decrease in cash, but also by strategic cost optimization and maintained long-term profitability targets.
• Employees: Potential impact from strategic cost structure optimization, which aims to yield at least $25 million in non-GAAP operating expense savings.
• Customers: Benefit from the successful launch and continued availability of Evolysse and Jeuveau, as well as the growth of the Evolus Rewards loyalty program.
• Suppliers: Increased inventory purchases ahead of potential tariffs may impact supply chain dynamics.
• Creditors: Financial performance, including increased losses and cash burn, could be relevant for assessing credit risk, though long-term profitability targets are maintained.

Next Steps

• Achieve meaningful profitability (positive non-GAAP operating income) in Q4 2025.
• Achieve annual profitability beginning in 2026.
• Launch Evolysse Sculpt in the United States in 2026.
• Launch Evolysse Lips in the United States in 2027.
• Continue to introduce Estyme in Europe through a limited experience program with select physician partners in the second half of 2025.
• Execute a broader European launch of Estyme in Q1 2026.
• Actively monitor developments regarding the 15% tariff on Evolysse and mitigate any potential future exposure.
• Work towards achieving $700 million in total net revenue and a 20% non-GAAP operating income margin by 2028.

Key Dates

Recommendation

While Evolus demonstrated strong performance with its Evolysse launch and international growth, the lowered full-year revenue guidance, increased operating losses, and a decline in cash are concerning short-term indicators. However, the company is taking decisive action through strategic cost optimization and maintains ambitious long-term revenue and profitability targets. For existing investors, holding the stock to observe the effectiveness of these strategic adjustments and the realization of future product launches seems prudent. For new investors, the current headwinds and revised guidance suggest a 'wait and see' approach until there's clearer evidence of a turnaround in U.S. toxin demand and sustained profitability.

Keywords

Evolus, EOLS, aesthetics, neurotoxin, Jeuveau, Evolysse, injectables, hyaluronic acid, HA gels, financial results, Q2 2025, earnings, guidance, profitability, cost optimization